Engineered Biomaterials for Cardiovascular Implants

用于心血管植入物的工程生物材料

• 批准号: 6538056
• 负责人: STEPHEN P MASSIA
• 金额: $ 9.7万
• 依托单位: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6538056
• 关键词: bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biomaterial interface interaction; biomaterials; cardiovascular system; drug delivery systems; gene delivery system; implant; laboratory rat; medical implant science; tissue engineering

DESCRIPTION (provided by applicant): Recent developments in the understanding of the failure of cardiovascular implants has led both the scientific and industrial communities searching for alternatives to provide optimum products. Over the past ten years, rapid advances in cell and molecular biology methodologies have led to a significant expansion of our knowledge base in vascular biology which potentially has application in every area of cardiovascular surgery and implant design. In recognition of the critical role that cell physiology, molecular biology, and other biomedical sciences play in improving implant performance, research and development efforts in cardiovascular implant science and engineering have recently focused on developing engineered biohybrid biomaterials that utilize synthetic biomaterials as well as cells, biochemicals, and extracellular matrix of cardiovascular tissues to develop a new generation of cardiovascular implants and related products that have more specific and longer-term performance goals than products that are currently on the market. The proposed work focuses on developing and applying biohybrid technologies for synthetic vascular grafts. Overall goal of the proposed study: Develop and evaluate the following four biohybrid technologies for improved performance of synthetic vascular grafts using specific implants and animal models currently under investigation by the PI: 1) bioactive biomaterial surface modifications; 2) bioactive degradable hydrogels; and 3) local drug/gene delivery systems and therapies. Hypotheses: The above described b1ohybrid technologies, namely bioactive biomaterial surface modifications, bioactive degradable hydrogels, and local drug/gene delivery system s/therapies will promote significant gains in long-term performance of synthetic vascular grafts. Combinations of these applied technologies will work in synergy to maximize graft performance. Aims: 1) Develop bioactive surface modifications on ePTFE (expanded polytetrafluoroethylene) vascular grafts and assess their effects on implant performance in vivo; 2) Develop degradable hydrogel formulations that can be impregnated into the porous space of ePTFE grafts for promoting angiogenesis in host tissues surrounding the implant, neovascularization of the ePTFE graft wall and luminal endothelialization via transmural growth of neovascular tissue; 3) Develop degradable hydrogel delivery vehicles that can be impregnated into ePTFE grafts for local drug/gene therapies targeting graft hyperplasia; and 4) Compare the impact of combinations of biohybrid technologies on graft performance to single technology approaches. Overall the proposed work will define biohybrid technologies that have promise for clinical application and will set the stage for further technology development. (End of Abstract)

描述（由申请人提供）： 心血管系统衰竭的认识进展 植入物导致科学界和工业界都在寻找 提供最佳产品的替代品。 在过去的十年里，快速 细胞和分子生物学方法学的进步已经导致了 扩大我们在血管生物学方面的知识基础， 应用于心血管外科和植入物设计的各个领域。 在 认识到细胞生理学、分子生物学和 其他生物医学科学在改善植入物性能、研究和 心血管植入物科学和工程的发展努力， 最近专注于开发工程生物混合生物材料， 合成生物材料以及细胞、生化物质和细胞外 基质的心血管组织开发新一代的心血管 植入物和相关产品，具有更具体和更长期的 性能目标比目前市场上的产品。 的 拟议的工作重点是开发和应用生物杂交技术， 人造血管移植物 拟议研究的总体目标： 评估以下四种生物混合技术，以提高 目前使用特定植入物和动物模型的合成血管移植物 PI正在研究：1）生物活性生物材料表面改性; 2)生物活性可降解水凝胶;和3）局部药物/基因递送系统， 治疗 假设：上述生物混合技术，即 生物活性生物材料表面改性，生物活性可降解水凝胶， 和局部药物/基因传递系统/疗法将促进显著的收益 人造血管移植物的长期性能。 这些的组合 应用的技术将协同工作，以最大限度地提高移植物的性能。 目的：1）在ePTFE（膨胀型）上开发生物活性表面改性 聚四氟乙烯）血管移植物，并评估其对植入物的影响 2）开发可降解的水凝胶制剂， 浸渍到ePTFE移植物的多孔空间中以促进血管生成 在植入物周围的宿主组织中，ePTFE移植物的新血管形成 通过新生血管的透壁生长的壁和腔内皮化 组织; 3）开发可降解的水凝胶递送载体， 浸渍到ePTFE移植物中，用于靶向移植物的局部药物/基因治疗 4）比较生物杂交组合的影响 技术对接枝性能的影响，以单一的技术方法。 总的来说，拟议的工作将确定有希望的生物杂交技术， 并将为进一步的技术奠定基础 发展 (End摘要）